Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors
Journal of Clinical Investigation · 01.11.2024 · 134 (21)
DOI: 10.1172/jci175790 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Investigation, online erschienen am 17.09.2024. Verfasst von Adham S Bear und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Receptors, Antigen, T-Cell, Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH, Lustgarten Foundation.
Abstract (Originalsprache)
BACKGROUND Neoantigens derived from KRAS MUT have been described, but the fine antigen specificity of T cell responses directed against these epitopes is poorly understood. Here, we explore KRAS MUT immunogenicity and the properties of 4 T cell receptors (TCRs) specific for KRAS G12V restricted to the HLA-A3 superfamily of class I alleles. METHODS A phase 1 clinical vaccine trial targeting KRAS MUT was conducted. TCRs targeting KRAS G12V restricted to HLA-A*03:01 or HLA-A*11:01 were isolated from vaccinated patients or healthy individuals. A comprehensive analysis of TCR antigen specificity, affinity, crossreactivity, and CD8 coreceptor dependence was performed. TCR lytic activity was evaluated, and target antigen density was determined by quantitative immunopeptidomics. RESULTS Vaccination against KRAS MUT resulted in the priming of CD8 + and CD4 + T cell responses. KRAS G12V -specific natural (not affinity enhanced) TCRs exhibited exquisite specificity to mutated protein with no discernible reactivity against KRAS WT . TCR-recognition motifs were determined and used to identify and exclude crossreactivity to noncognate peptides derived from the human proteome. Both HLA-A*03:01 and HLA-A*11:01–restricted TCR-redirected CD8 + T cells exhibited potent lytic activity against KRAS G12V cancers, while only HLA-A*11:01–restricted TCR-T CD4 + T cells exhibited antitumor effector functions consistent with partial coreceptor dependence. All KRAS G12V -specific TCRs displayed high sensitivity for antigen as demonstrated by their ability to eliminate tumor cell lines expressing low levels of peptide/HLA (4.4 to 242) complexes per cell. CONCLUSION This study identifies KRAS G12V -specific TCRs with high therapeutic potential for the development of TCR-T cell therapies. TRIAL REGISTRATION ClinicalTrials.gov NCT03592888. FUNDING AACR SU2C/Lustgarten Foundation, Parker Institute for Cancer Immunotherapy, and NIH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine.
- The College of Arts and Sciences.
- Abramson Cancer Center, and.
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- MSBioworks, Ann Arbor, Michigan, USA.
- Department of Pathology and Laboratory Medicine and.
Förderung
- NCI NIH HHS
- NIH
- Lustgarten Foundation
Zitieren
APA
Bear, A. S., Nadler, R. B., O'Hara, M. H., Stanton, K. L., Xu, C., Saporito, R. J., Rech, A. J., Baroja, M. L., Blanchard, T., Elliott, M. H., Ford, M. J., Jones, R., Patel, S., Brennan, A., O'Neil, Z., Powell, D. J., Vonderheide, R. H., Linette, G. P., & Carreno, B. M. (2024). Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. Journal of Clinical Investigation, 134(21). https://doi.org/10.1172/jci175790
Vancouver
Bear AS, Nadler RB, O'Hara MH, Stanton KL, Xu C, Saporito RJ, et al. Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. Journal of Clinical Investigation. 2024;134(21). doi:10.1172/jci175790
BibTeX
@article{Bear2024,
author = {Bear, Adham S and Nadler, Rebecca B and O'Hara, Mark H and Stanton, Kelsey L and Xu, Chong and Saporito, Robert J and Rech, Andrew J and Baroja, Miren L and Blanchard, Tatiana and Elliott, Maxwell H and Ford, Michael J and Jones, Richard and Patel, Shivang and Brennan, Andrea and O'Neil, Zachary and Powell, Daniel J and Vonderheide, Robert H and Linette, Gerald P and Carreno, Beatriz M},
title = {Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {21},
doi = {10.1172/jci175790}
}
EUVIMED